ImmunoSkin, Almirall’s annual scientific meeting for the discussion of chronic inflammatory skin conditions, has been held for the fourth time, gathering international experts to consider advances in science and treatment.

This year’s ImmunoSkin was chaired by Dr Christian Vestergaard, professor and dermatologist at the Department of Dermatology, Aarhus University Hospital, Denmark. 

Discussions centered around four key drivers of treatment success in immune-modulated skin diseases: new concepts in skin immunology; clinical perspectives; patient perspectives, and recent and future dermatology innovations.

Vestergaard said: “ImmunoSkin is a unique opportunity to focus on advancing our understanding of inflammatory skin diseases and their treatments. 

“The focus on collaboration and scientific exchange, paired with sharing foundational patient insights on inflammatory skin diseases and treatment outcomes, is immensely powerful to further drive treatment success and patient outcomes for some of the most debilitating dermatological conditions.”

The meeting featured workshops on the treatment of a variety of skin conditions, such as atopic dermatitis and psoriasis, and the latest advances in treating them. 

There was also a strong focus on patient experience, reflecting the World Health Organisation’s (WHO) 2025 resolution on skin diseases as a global public health priority, emphasising the importance of considering the impact of skin diseases on both the patients’ psychological well-being and their partners and families.

ImmunoSkin is an international meeting for dermatologists, nurturing networking and collaboration across the dermatology sector..

“Advancing science and treatment success for skin diseases is based on collaboration and expert exchange – this is what the multifaceted and meaningful exchange at ImmunoSkin facilitates,” said Volker Koscielny, chief medical officer at Almirall.